Maraldo David R. has filed an amended ownership report, which indicates changes in beneficial ownership of securities. This filing is significant as it highlights ongoing adjustments within the pharmaceutical industry, particularly involving major players like Merck & Co., Inc.

Maraldo David R. is categorized as an individual filer with no specific SIC or tickers associated with his filings. The recent filing was submitted on October 22, 2026, as a Form 3/A, which is an initial statement of beneficial ownership of securities.

The filing states, "This is an amended statement of beneficial ownership of securities." It is part of a series of recent filings, including a Form 4 submitted on August 7, 2026, and a Form 144 on August 5, 2026.

This update may affect stakeholders and investors who are monitoring changes in ownership within the pharmaceutical sector, particularly those with interests in Merck & Co., Inc., which is identified as the issuer in this filing.

The filing does not say what happens next.

Filing Details

The Form 3/A was filed on October 22, 2026, with an acceptance date of the same day at 16:05:53. This amended statement reflects beneficial ownership as of May 1, 2026, indicating a specific reporting period that may provide insights into recent transactions or changes in holdings.

Maraldo David R.'s filing is categorized under the SEC's Act 34, and it is associated with the SEC File Number 001-06571. The filing also includes a complete submission text file, which is available for public access.

Company Information

Merck & Co., Inc., the issuer linked to this filing, has a Central Index Key (CIK) of 0000310158 and is classified under Standard Industrial Code (SIC) 2834, which pertains to Pharmaceutical Preparations. This classification highlights the company's focus within the broader pharmaceutical industry.

Mailing Address for Maraldo David R.: 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065.
Business Address for Merck & Co., Inc.: 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, with a contact number of 908-740-4000.

The filing does not provide specific details about the nature of the changes in ownership or the number of shares involved in the amendment.